Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report.
Thirty stage I patients with invasive ovarian adenocarcinoma were treated with 6 months of adjuvant induction cisplatin and monthly cisplatin, adriamycin, and cyclophosphamide. To date, 97% (29) are alive with no evidence of disease and normal CA-125 levels and 93% (28) are alive progression free with a median follow-up of 34 months (13-56).